Table 4 Study-level descriptive statistics (n = 35)
| Â | Total (%) |
|---|---|
Median publication year (range) | 2013 (2003–2017) |
Implementation research framework | 0 (0%) |
Study designa | |
 Qualitative | 20 (57%) |
 Cross-sectional | 8 (23%) |
 Cohort | 1 (3%) |
 Non-randomized pre/post without control | 7 (20%) |
 Non-randomized pre/post with control | 3 (9%) |
 Individual randomized controlled trial | 2 (6%) |
 Cluster randomized controlled trial | 6 (17%) |
 Policy analysis | 0 (0%) |
 Economic evaluation | 2 (6%) |
 Other | 3 (9%) |
Study type | |
 Effectiveness | 1 (3%) |
 Type 1 hybrid | 32 (91%) |
 Type 2 hybrid | 0 (0%) |
 Type 3 hybrid | 0 (0%) |
 Implementation | 2 (6%) |
Implementation stage | |
 Pilot/once-off | 29 (83%) |
 Scaling up | 0 (0%) |
 Implemented and sustained at scale | 6 (17%) |
 De-implementation | 0 (0%) |
Study populationa | |
 Community | 28 (80%) |
 Patients | 13 (37%) |
 Providers | 10 (29%) |
 Policy-makers | 3 (9%) |
Implementation outcomes reporteda | |
 Acceptability | 20 (57%) |
 Adoption | 1 (3%) |
 Appropriateness | 5 (14%) |
 Cost | 2 (6%) |
 Feasibility | 14 (40%) |
 Fidelity | 4 (11%) |
 Penetration | 6 (17%) |
 Sustainability | 2 (6%) |
Implementation outcome reportinga | |
 Mean reporting score (SD) | 40% (30%) |
 Included in study objectives? | 14 (40%) |
 Hypothesis or conceptual model stated? | 3 (9%) |
 Methods for outcomes specified? | 28 (80%) |
 Used validated measure(s)? | 0 (0%) |
 Sample size specified? | 24 (69%) |
Other outcomes reporteda | |
 Stigma | 25 (71%) |
 Service delivery | 12 (34%) |
 Patient health | 7 (20%) |
 Other | 13 (37%) |